Key clinical point: Use of the urate-lowering therapy febuxostat decreased from 10% of gout patients in 2013 and 2014 to 6% in 2019.
Major finding: The overall number of gout patients using urate-lowering therapy increased slightly from 567 per 1,000 patients to 656 per 1,000 patients between 2009 and 2019.
Study details: The data come from a review of claims data from a nationwide health plan in the United States including use of urate-lowering therapy between Jan. 1, 2009, and Dec. 31, 2019.
Disclosures: The study was supported by the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital. Dr. Kim disclosed receiving research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Roche, and Bristol-Myers Squibb for research unrelated to the current study.
Kim SC et al. Arthritis Rheumatol. 2020 Oct 7. doi: 10.1002/art.41550.